Related references
Note: Only part of the references are listed.Combination therapy of cisplatin with cilastatin enables an increased dose of cisplatin, enhancing its antitumor effect by suppression of nephrotoxicity
Masashi Arita et al.
SCIENTIFIC REPORTS (2021)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Cisplatin-loaded PLGA nanoparticles for HER2 targeted ovarian cancer therapy
Rossina Dominguez-Rios et al.
COLLOIDS AND SURFACES B-BIOINTERFACES (2019)
A structure-based mechanism of cisplatin resistance mediated by glutathione transferase P1-1
Anastasia De Luca et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Advances in Toxicological Research of the Anticancer Drug Cisplatin
Luyu Qi et al.
CHEMICAL RESEARCH IN TOXICOLOGY (2019)
A thermo-responsive alginate nanogel platform co-loaded with gold nanoparticles and cisplatin for combined cancer chemo-photothermal therapy
Mehri Mirrahimi et al.
PHARMACOLOGICAL RESEARCH (2019)
Cisplatin-conjugated gold nanoparticles as a theranostic agent for head and neck cancer
Erez Shmuel Davidi et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2018)
Cisplatin based therapy: the role of the mitogen activated protein kinase signaling pathway
Iman W. Achkar et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2018)
AS1411 aptamer-decorated cisplatin-loaded poly(lactic-co-glycolic acid) nanoparticles for targeted therapy of miR-21-inhibited ovarian cancer cells
Somayeh Vandghanooni et al.
NANOMEDICINE (2018)
Phase II Study of Irinotecan and Cisplatin Combination Chemotherapy in Metastatic, Unresectable Esophageal Cancer
Miso Kim et al.
CANCER RESEARCH AND TREATMENT (2017)
Use of mechanistic data in the IARC evaluations of the carcinogenicity of polychlorinated biphenyls and related compounds
Beatrice Lauby-Secretan et al.
ENVIRONMENTAL SCIENCE AND POLLUTION RESEARCH (2016)
Doxorubicin- and cisplatin-loaded nanostructured lipid carriers for breast cancer combination chemotherapy
Huifeng Di et al.
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY (2016)
C-Jun N-terminal kinase signalling pathway in response to cisplatin
Dong Yan et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2016)
Clinical potential of necitumumab in non-small cell lung carcinoma
Carlo Genova et al.
ONCOTARGETS AND THERAPY (2016)
Osthole induces lung cancer cell apoptosis through inhibition of inhibitor of apoptosis family proteins
Xiao-Man Xu et al.
ONCOLOGY LETTERS (2016)
Roles of p38α mitogen-activated protein kinase in mouse models of inflammatory diseases and cancer
Jalaj Gupta et al.
FEBS JOURNAL (2015)
Molecular mechanisms of cisplatin cytotoxicity in acute promyelocytic leukemia cells
Sanjay Kumar et al.
ONCOTARGET (2015)
Cisplatin in cancer therapy: Molecular mechanisms of action
Shaloam Dasari et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2014)
Cardiotoxicity: Cisplatin and long-term cancer survivors
Salvatore Patane
INTERNATIONAL JOURNAL OF CARDIOLOGY (2014)
Efficacy of Cisplatin-loaded poly butyl cyanoacrylate nanoparticles on the ovarian cancer: an in vitro study
Seyed Kazem Bagherpour Doun et al.
TUMOR BIOLOGY (2014)
p38α MAPK pathway: A key factor in colorectal cancer therapy and chemoresistance
Valentina Grossi et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2014)
Inhibition of p38 MAPK sensitizes tumour cells to cisplatin-induced apoptosis mediated by reactive oxygen species and JNK
Lorena Pereira et al.
EMBO MOLECULAR MEDICINE (2013)
Tetraarsenic oxide and cisplatin induce apoptotic synergism in cervical cancer
Jung Mi Byun et al.
ONCOLOGY REPORTS (2013)
Targeted Delivery of Cisplatin to Lung Cancer Using ScFvEGFR-Heparin-Cisplatin Nanoparticles
Xiang-Hong Peng et al.
ACS NANO (2011)
Cisplatin-induced cardiotoxicity Mechanisms and cardioprotective strategies
El-Sayed E. El-Awady et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2011)
Multicenter, phase II study of gemcitabine and S-1 combination chemotherapy in patients with advanced biliary tract cancer
Takashi Sasaki et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2010)
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer.
Juan Valle et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Michele Peyrone (1813-1883), Discoverer of Cisplatin
George B. Kauffman et al.
PLATINUM METALS REVIEW (2010)
Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy
Nagesh Kolishetti et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Cellular Responses to Cisplatin-Induced DNA Damage
Alakananda Basu et al.
JOURNAL OF NUCLEIC ACIDS (2010)
A Systematic Review of Genes Involved in the Inverse Resistance Relationship Between Cisplatin and Paclitaxel Chemotherapy: Role of BRCA1
Britta Stordal et al.
CURRENT CANCER DRUG TARGETS (2009)
Doxorubicin: The Good, the Bad and the Ugly Effect
Cristina Carvalho et al.
CURRENT MEDICINAL CHEMISTRY (2009)
Development of Cell Cycle Inhibitors for Cancer Therapy
Gary K. Schwartz et al.
Current Oncology (2009)
Hereditary ovarian carcinoma: Heterogeneity, molecular genetics, pathology, and management
Henry T. Lynch et al.
MOLECULAR ONCOLOGY (2009)
A phase II study of paclitaxel and capecitabine as a first-line combination chemotherapy for advanced gastric cancer
H. J. Kang et al.
BRITISH JOURNAL OF CANCER (2008)
c-Abl activates p38 MAPK independently of its tyrosine kinase activity:: Implications in cisplatin-based therapy
Eva M. Galan-Moya et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
Cisplatin nephrotoxicity: A review
Xin Yao et al.
AMERICAN JOURNAL OF THE MEDICAL SCIENCES (2007)
Protein kinase Cε makes the life and death decision
Alakananda Basu et al.
CELLULAR SIGNALLING (2007)
Anticancer activity of cisplatin-loaded PLGA-mPEG nanoparticles on LNCaP prostate cancer cells
Evangelos C. Gryparis et al.
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS (2007)
Biochemical Mechanisms of Cisplatin Cytotoxicity
Victoria Cepeda et al.
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY (2007)
Phase II study of capecitabine and irinotecan combination chemotherapy in patients with advanced gastric cancer
J. H. Baek et al.
BRITISH JOURNAL OF CANCER (2006)
Intraperitoneal cisplatin and paclitaxel in ovarian cancer
DK Armstrong et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Activation of ERK during DNA damage-induced apoptosis involves protein kinase Cδ
A Basu et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2005)
Essential role of p53 phosphorylation by p38 MAPK in apoptosis induction by the HIV-1 envelope
JL Perfettini et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
Caspase activation - stepping on the gas or releasing the brakes? Lessons from humans and flies
GS Salvesen et al.
ONCOGENE (2004)
The effects of erdosteine on the activities of some metabolic enzymes during cisplatin-induced nephrotoxicity in rats
HR Yilmaz et al.
PHARMACOLOGICAL RESEARCH (2004)
Role of non-selective adenosine receptor blockade and phosphodiesterase inhibition in cisplatin-induced nephrogonadal toxicity in rats
SY Saad et al.
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY (2004)
Platinum-based anticancer agents: Innovative design strategies and biological perspectives
YP Ho et al.
MEDICINAL RESEARCH REVIEWS (2003)
Ovarian cancer: Strategies for overcoming resistance to chemotherapy
R Agarwal et al.
NATURE REVIEWS CANCER (2003)
Decision making by p53: life, death and cancer
M Oren
CELL DEATH AND DIFFERENTIATION (2003)
Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases
GL Johnson et al.
SCIENCE (2002)
Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals
S Ishida et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Cisplatin-induced renal cell apoptosis: Caspase 3-dependent and -independent pathways
BS Cummings et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2002)
Cisplatin-induced peripheral neurotoxicity in rats reduces the circulating levels of nerve growth factor
G Cavaletti et al.
NEUROSCIENCE LETTERS (2002)
Ten years of protein kinase B signalling: a hard Akt to follow
DP Brazil et al.
TRENDS IN BIOCHEMICAL SCIENCES (2001)
Enhanced ROS production in oncogenically transformed cells potentiates c-Jun N-terminal kinase and p38 mitogen-activated protein kinase activation and sensitization to genotoxic stress
M Benhar et al.
MOLECULAR AND CELLULAR BIOLOGY (2001)
Protective role for c-Jun in the cellular response to DNA damage
O Potapova et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Is cisplatin-induced cell death always produced by apoptosis?
VM Gonzalez et al.
MOLECULAR PHARMACOLOGY (2001)
Effect of extracellular signal-regulated kinase on p53 accumulation in response to cisplatin
DL Persons et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Translocation of SAPK/JNK to mitochondria and interaction with Bcl-xL in response to DNA damage
S Kharbanda et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Share Paper
